文献速递慢性肾脏病

肾脏病学趋势:从支持治疗到慢性肾脏病联合治疗

Trends in nephrology: from "supportive care" to CKD combination therapy.
PubMed 文献 · Nephrol Dial Transplant · 2026-01-01

慢性肾脏病(CKD)管理已从单用肾素-血管紧张素系统抑制剂(RASi)的支持治疗,演变为多靶点联合治疗。SGLT2i、GLP-1RA和nsMRA通过代谢、血流动力学和炎症通路提供互补肾脏保护。大规模研究显示四联疗法在减少糖尿病肾衰竭风险上优于单药治疗,且安全性互补。KDIGO 2024指南强调以患者为中心、团队为基础的管理并整合这些疗法。

要点

  • RASi仍是基础,但残留白蛋白尿和高钾血症等限制其充分预防进展。
  • SGLT2i、GLP-1RA和nsMRA在CKM框架下提供互补肾脏保护。
  • 四联疗法在糖尿病患者中减少肾衰竭风险优于单药,安全性互补。

核心结论

  • CKD管理已从RASi单药支持治疗转向多靶点联合治疗,四联疗法在糖尿病CKD患者中减少肾衰竭风险优于单药治疗。

研究设计与样本

  • 本文为综述,总结CKD治疗演变及大规模研究证据。

主要发现

  • RASi在完全预防疾病进展方面疗效有限,并存在高钾血症等安全性顾虑。
  • SGLT2i、GLP-1RA和nsMRA通过代谢、血流动力学和炎症通路发挥互补肾脏保护作用。
  • 大规模研究显示四联疗法在糖尿病患者中减少肾衰竭风险优于单药,且安全性互补。
  • SGLT2i联合RASi可减轻高钾血症风险并减少RASi停药,从而提高治疗持续性。

关键数值与推荐

  • KDIGO 2024 CKD评估与管理临床实践指南强调以患者为中心、团队为基础的管理并整合这些疗法。

临床怎么用

  • 在CKD管理中,可考虑在RASi基础上联合SGLT2i、GLP-1RA和nsMRA以增强肾脏保护。
  • SGLT2i与RASi联用有助于降低高钾血症风险并改善RASi持续使用。

局限性

  • 非糖尿病CKD人群的证据仍需扩展。
  • 四联疗法的快速实施及醛固酮合成酶抑制剂等新疗法的证据尚待补充。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic kidney disease (CKD) management has evolved from supportive care with renin-angiotensin system inhibitors (RASi) alone to multi-target combination therapies. While RASi remain foundational, their limited efficacy in fully preventing disease progression (e.g. residual albuminuria) and safety concerns, such as hyperkalemia, have underscored the need for novel therapeutic agents. Sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RA) and nonsteroidal mineralocorticoid receptor antagonists (nsMRA) demonstrate complementary nephroprotective effects by targeting metabolic, hemodynamic and inflammatory pathways within the cardiovascular-kidney-metabolic (CKM) syndrome framework. Evidence from large-scale studies demonstrates that combination four-pillar therapies are superior to monotherapy in reducing the risk of kidney failure in patients with diabetes and also exhibit complementary safety profiles that enhance tolerability and long-term patient adherence. For example, combining SGLT2i with RASi mitigates hyperkalemia risk and reduces RASi discontinuation, thereby enhancing treatment persistence. The KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD emphasizes patient-centered, team-based management integrating these therapies. Future directions include expanding evidence for non-diabetic CKD populations, more rapid implementation of these four-pillar therapies and new therapies such as aldosterone synthase inhibitors in this vulnerable group.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. He K, Guo Y, Yang C, et al. Trends in nephrology: from "supportive care" to CKD combination therapy. Nephrol Dial Transplant. 2026. PMID: 41533660. doi:10.1093/ndt/gfag003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。